The short version
- The trial showed a 42 percent reduction in the risk of death or disease recurrence among patients receiving the personalized vaccine alongside immunotherapy.
- Researchers used mRNA technology to create individualized vaccines based on genetic analysis of each patient's removed tumor tissue.
- While results are promising, experts caution that long-term data is needed to confirm overall survival benefits and applicability to other cancer types.
A clinical trial involving more than 1,100 patients has demonstrated that a personalized mRNA vaccine, when administered with an established immunotherapy drug, significantly reduces the risk of melanoma returning or spreading. The study found that the combination therapy cut the likelihood of disease recurrence or death by 42 percent over a two-year period. Additionally, the treatment reduced the risk of the cancer metastasizing across the body by 38 percent during the same timeframe.
The experimental approach targets individuals who have already undergone surgical removal of their tumors. Participants in the study received Keytruda, a widely used immunotherapy agent designed to help the immune system identify and destroy cancer cells. Approximately two-thirds of the 1,137 adult participants also received Intismeran, an experimental vaccine developed by MSD and Moderna. The remaining participants were given a placebo to serve as a control group.
Intismeran utilizes mRNA technology similar to that found in certain coronavirus vaccines. However, unlike mass-produced shots, this vaccine is customized for each patient. Scientists analyze the genetic makeup of the tumor removed from the patient to identify specific mutations. This information is then used to create a vaccine that trains the immune system to recognize and attack cells bearing those unique markers, potentially preventing residual cancer cells from causing a relapse.
Tony Chapman, a 75-year-old participant from Corby in the East Midlands, was diagnosed with melanoma in 2019. After initial surgery, the cancer returned in his lymph nodes, requiring a second operation. He volunteered for the trial to contribute to scientific progress and potentially benefit from the treatment. Three years after his initial diagnosis, Chapman remains cancer-free, though he does not know whether he received the active vaccine or the placebo.
Professor Pippa Corrie, a consultant medical oncologist at Addenbrooke's Hospital in Cambridge who helped oversee part of the study, described the findings as a significant proof of principle. She noted that personalization represents an exciting next step in cancer care. However, she emphasized that further evidence is required to fully demonstrate the treatment's value and long-term impact on patient survival rates.
Independent experts have reacted with cautious optimism. Professor Alan Melcher from the Institute of Cancer Research in London called the results very impressive but warned against assuming the approach will work equally well for all types of cancer. He stressed that longer follow-up periods are essential to understand the effect on overall survival and to determine if the benefits observed in melanoma translate to other malignancies.
MSD and Moderna have indicated they are engaging with regulatory authorities, suggesting that approval applications could be filed as early as next year. The companies are already testing similar personalized vaccine approaches against other tumors, including kidney, bladder, and lung cancers. Stock prices for both firms surged following initial hints of success but experienced volatility after analysts noted the results were not as strong as those seen in earlier, smaller trials.
Widespread adoption of this treatment faces practical hurdles, particularly regarding cost. Because each vaccine must be individually manufactured based on a patient's specific tumor genetics, the process is resource-intensive. In the United Kingdom, broad implementation through the National Health Service will depend heavily on cost-effectiveness assessments. The ongoing trial will continue to monitor participants to gather more data on long-term outcomes and survival benefits.
The study highlights a growing trend toward precision medicine in oncology. By tailoring treatments to the unique genetic profile of an individual's cancer, researchers aim to improve efficacy and reduce side effects compared to traditional chemotherapy or broad-spectrum immunotherapies. While this trial focuses on melanoma, the underlying technology offers a framework that could potentially be adapted for other diseases if future studies confirm its safety and effectiveness across different patient populations.
As regulators review the data, the medical community awaits confirmation of whether this personalized approach can become a standard part of post-surgical care for high-risk cancer patients. The success of Intismerad in preventing recurrence suggests that mRNA technology may have applications far beyond infectious diseases. However, until long-term survival data is available, the treatment remains an experimental option within clinical trials rather than a widely accessible therapy.
Sources behind this briefing
Go to the original reporting
- BBC News↗First personalised cancer vaccine cuts risk of disease returning in major trial
